Brett Leav

7.6k total citations · 2 hit papers
36 papers, 2.0k citations indexed

About

Brett Leav is a scholar working on Infectious Diseases, Epidemiology and Immunology. According to data from OpenAlex, Brett Leav has authored 36 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Infectious Diseases, 19 papers in Epidemiology and 7 papers in Immunology. Recurrent topics in Brett Leav's work include Influenza Virus Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and Respiratory viral infections research (8 papers). Brett Leav is often cited by papers focused on Influenza Virus Research Studies (11 papers), SARS-CoV-2 and COVID-19 Research (9 papers) and Respiratory viral infections research (8 papers). Brett Leav collaborates with scholars based in United States, Finland and Philippines. Brett Leav's co-authors include Deborah C. Molrine, Barbra M. Blair, Donna M. Ambrosino, Roger Baxter, Mark D. Leney, Israel Lowy, Dale N. Gerding, Honorine Ward, Susan Sloan and William D. Thomas and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Gastroenterology.

In The Last Decade

Brett Leav

36 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment with Monoclonal Antibodies against Clostridium difficile Toxins

2010 557 citations Israel Lowy, Deborah C. Molrine et al. New England Journal of Medicine profile →
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

2023 97 citations Brandon Essink, Laurence Chu et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brett Leav United States	19	1.3k	880	303	296	238	36	2.0k
Filip Dubovsky United States	29	983 0.7×	1.5k 1.7×	313 1.0×	81 0.3×	332 1.4×	53	2.6k
Nadine Rouphael United States	27	1.4k 1.0×	1.5k 1.7×	638 2.1×	92 0.3×	949 4.0×	122	3.3k
Lucina Titone Italy	25	887 0.7×	750 0.9×	140 0.5×	382 1.3×	298 1.3×	76	1.9k
Susanne Dudman Norway	22	815 0.6×	1.1k 1.3×	242 0.8×	198 0.7×	207 0.9×	74	1.8k
Szu‐Min Hsieh Taiwan	27	1.5k 1.1×	1.3k 1.5×	185 0.6×	144 0.5×	254 1.1×	162	2.6k
Jin Han Kang South Korea	24	693 0.5×	984 1.1×	214 0.7×	59 0.2×	105 0.4×	203	2.0k
Johan Vekemans United Kingdom	35	948 0.7×	1.2k 1.4×	479 1.6×	149 0.5×	1.3k 5.6×	69	3.5k
Birthe Høgh Denmark	28	373 0.3×	675 0.8×	317 1.0×	265 0.9×	660 2.8×	77	2.4k
Mario Corbellino Italy	23	1.2k 0.9×	735 0.8×	205 0.7×	311 1.1×	196 0.8×	48	2.5k
Thomas Luke United States	15	1.1k 0.8×	405 0.5×	357 1.2×	180 0.6×	367 1.5×	26	2.2k

Countries citing papers authored by Brett Leav

Since Specialization

Citations

This map shows the geographic impact of Brett Leav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett Leav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett Leav more than expected).

Fields of papers citing papers by Brett Leav

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett Leav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett Leav. The network helps show where Brett Leav may publish in the future.

Co-authorship network of co-authors of Brett Leav

This figure shows the co-authorship network connecting the top 25 collaborators of Brett Leav. A scholar is included among the top collaborators of Brett Leav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett Leav. Brett Leav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Giuliano, Anna R., Barbara J. Kuter, Shari Pilon‐Thomas, et al.. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications. 43(7). 749–764. 6 indexed citations

Leav, Brett, et al.. (2023). No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial. Clinical Infectious Diseases. 77(9). 1238–1246. 6 indexed citations

Hejazi, Nima S., Xiaoying Shen, Lindsay N. Carpp, et al.. (2023). Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial. International Journal of Infectious Diseases. 137. 28–39. 2 indexed citations

Essink, Brandon, Laurence Chu, Elizabeth Barranco, et al.. (2023). The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. The Lancet Infectious Diseases. 23(5). 621–633. 97 indexed citations breakdown →

Chu, Laurence, Keith Vrbicky, David C. Montefiori, et al.. (2022). Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nature Medicine. 28(5). 1042–1049. 56 indexed citations

Leav, Brett, Walter L. Straus, P. White, et al.. (2022). A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine. 40(35). 5275–5293. 5 indexed citations

Chalkias, Spyros, Frank Eder, Brandon Essink, et al.. (2022). Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nature Medicine. 28(11). 2388–2397. 70 indexed citations

Beran, Jiřı́, Humberto Reynales, Airi Põder, et al.. (2021). Prevention of influenza during mismatched seasons in older adults with an MF59-adjuvanted quadrivalent influenza vaccine: a randomised, controlled, multicentre, phase 3 efficacy study. The Lancet Infectious Diseases. 21(7). 1027–1037. 33 indexed citations

Chu, Laurence, Roderick McPhee, Wenmei Huang, et al.. (2021). A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine. 39(20). 2791–2799. 146 indexed citations

10.

Heeringa, Marten, et al.. (2020). Comparability of Titers of Antibodies against Seasonal Influenza Virus Strains as Determined by Hemagglutination Inhibition and Microneutralization Assays. Journal of Clinical Microbiology. 58(9). 15 indexed citations

11.

Otten, Gillis R., et al.. (2019). A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age. Vaccine. 38(3). 578–587. 3 indexed citations

12.

Nicolay, Uwe, Esther Heijnen, Pantaleo Nacci, P. Patriarca, & Brett Leav. (2019). Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. International Journal of Infectious Diseases. 85. S1–S9. 35 indexed citations

13.

Lindert, Kelly, Brett Leav, Esther Heijnen, Julia Barrett, & Uwe Nicolay. (2019). Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children and adults 65 years of age and older. International Journal of Infectious Diseases. 85. S10–S17. 10 indexed citations

14.

Leav, Brett, et al.. (2018). 2556. Retrospective Evaluation of Mismatch From Egg-Based Isolation of Influenza Strains Compared With Cell-Based Isolation and the Possible Implications for Vaccine Effectiveness. Open Forum Infectious Diseases. 5(suppl_1). S69–S69. 18 indexed citations

15.

Vesikari, Timo, Judith L. Kirstein, Brett Leav, et al.. (2018). Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. The Lancet Respiratory Medicine. 6(5). 345–356. 47 indexed citations

16.

Morin, Trevor J., Teresa J. Broering, Brett Leav, et al.. (2012). Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees. PLoS Pathogens. 8(8). e1002895–e1002895. 133 indexed citations

17.

Lowy, Israel, Deborah C. Molrine, Brett Leav, et al.. (2010). Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. New England Journal of Medicine. 362(3). 197–205. 557 indexed citations breakdown →

18.

Leav, Brett, Barbra M. Blair, Mark D. Leney, et al.. (2009). Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 28(4). 965–969. 193 indexed citations

19.

Leav, Brett, et al.. (1993). Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats.. PubMed. 68(1). 33–44. 29 indexed citations

20.

Neiman, Richard S., Anthony J. Janckila, L T Yam, et al.. (1990). The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization.. PubMed. 136(3). 717–23. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact